Drug Trial Radar · NCT05023018
NEO100 and High-Grade Meningioma
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 1, 2022
Primary completion
Dec 30, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Neonc Technologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.
Conditions
- Residual, Progressive or Recurrent Grade II or III Meningioma
Interventions
NEO100Drug
NEO100 is a purified form of perillyl alcohol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival as six months (PFS6).Time frame: 6 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California · Recruiting
Sutter Health Research Institute
San Francisco, California · Recruiting
Saint John Cancer Institute
Santa Monica, California · Recruiting
Tufts Medical Center
Boston, Massachusetts · Recruiting
Baylor Scott and White
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.